Brain clocks captured the diversity and disparities in accelerated aging and dementia in 15 countries. (Nature Medicine)
The FBI released a redacted portion of a report on Havana syndrome that was one of the first to suggest the mysterious ailments were the result of “social contagion.” (New York Times)
Researchers mapped out how morphine relieves pain, identifying a select set of neurons that formed a “morphine ensemble.” (Science)
Electroencephalographic abnormalities in COVID-19 patients resembled those seen in early stages of Alzheimer’s and related dementia, a systematic review showed. (Alzheimer’s and Dementia)
Early treatment of a first acute myelin oligodendrocyte glycoprotein antibody-associated disease attack was associated with a lower risk of a relapsing disease course. (JAMA Neurology)
The investigational Bruton’s tyrosine kinase inhibitor tolebrutinib met its primary endpoint of delaying disability progression onset in a phase III study of people with non-relapsing secondary progressive multiple sclerosis (MS), but failed to reduce relapses in studies of relapsing MS versus teriflunomide (Aubagio), Sanofi said.
To date, real-life studies have not shown that soft-shelled helmet padding like the Guardian Cap reduced brain injuries in American football, CNN reported.
The risk of dementia associated with SGLT-2 inhibitors — mainly dapagliflozin (Farxiga) and empagliflozin (Jardiance) — was less than that with DPP-4 inhibitors in people with type 2 diabetes, according to Korean data. (The BMJ)
Cholinesterase inhibitors slowed cognitive decline over 5 years in people who had dementia with Lewy bodies compared with both nonuse and memantine (Namenda), Swedish registry data showed. (Alzheimer’s and Dementia)
A phase III trial showed that the orexin receptor antagonist suvorexant (Belsomra) did not significantly reduce delirium in older adults at high risk for delirium after hospitalization. (JAMA Network Open)
Please enable JavaScript to view the